26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Polysialic acid blocks mononuclear phagocyte reactivity, inhibits complement activation, and protects from vascular damage in the retina

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Age‐related macular degeneration (AMD) is a major cause of blindness in the elderly population. Its pathophysiology is linked to reactive oxygen species (ROS) and activation of the complement system. Sialic acid polymers prevent ROS production of human mononuclear phagocytes via the inhibitory sialic acid‐binding immunoglobulin‐like lectin‐11 (SIGLEC11) receptor. Here, we show that low‐dose intravitreal injection of low molecular weight polysialic acid with average degree of polymerization 20 (polySia avDP20) in humanized transgenic mice expressing SIGLEC11 on mononuclear phagocytes reduced their reactivity and vascular leakage induced by laser coagulation. Furthermore, polySia avDP20 prevented deposition of the membrane attack complex in both SIGLEC11 transgenic and wild‐type animals. In vitro, polySia avDP20 showed two independent, but synergistic effects on the innate immune system. First, polySia avDP20 prevented tumor necrosis factor‐α, vascular endothelial growth factor A, and superoxide production by SIGLEC11‐positive phagocytes. Second, polySia avDP20 directly interfered with complement activation. Our data provide evidence that polySia avDP20 ameliorates laser‐induced damage in the retina and thus is a promising candidate to prevent AMD‐related inflammation and angiogenesis.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease.

          Age-related macular degeneration (AMD), a blinding disorder that compromises central vision, is characterized by the accumulation of extracellular deposits, termed drusen, between the retinal pigmented epithelium and the choroid. Recent studies in this laboratory revealed that vitronectin is a major component of drusen. Because vitronectin is also a constituent of abnormal deposits associated with a variety of diseases, drusen from human donor eyes were examined for compositional similarities with other extracellular disease deposits. Thirty-four antibodies to 29 different proteins or protein complexes were tested for immunoreactivity with hard and soft drusen phenotypes. These analyses provide a partial profile of the molecular composition of drusen. Serum amyloid P component, apolipoprotein E, immunoglobulin light chains, Factor X, and complement proteins (C5 and C5b-9 complex) were identified in all drusen phenotypes. Transcripts encoding some of these molecules were also found to be synthesized by the retina, retinal pigmented epithelium, and/or choroid. The compositional similarity between drusen and other disease deposits may be significant in view of the recently established correlation between AMD and atherosclerosis. This study suggests that similar pathways may be involved in the etiologies of AMD and other age-related diseases.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Complement control protein factor H: the good, the bad, and the inadequate.

            The complement system is an essential component of the innate immune system that participates in elimination of pathogens and altered host cells and comprises an essential link between the innate and adaptive immune system. Soluble and membrane-bound complement regulators protect cells and tissues from unintended complement-mediated injury. Complement factor H is a soluble complement regulator essential for controlling the alternative pathway in blood and on cell surfaces. Normal recognition of self-cell markers (i.e. polyanions) and C3b/C3d fragments is necessary for factor H function. Inadequate recognition of host cell surfaces by factor H due to mutations and polymorphisms have been associated with complement-mediated tissue damage and disease. On the other hand, unwanted recognition of pathogens and altered self-cells (i.e. cancer) by factor H is used as an immune evasion strategy. This review will focus on the current knowledge related to these versatile recognition properties of factor H. Copyright 2010 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization.

              Macrophage recruitment to the choroid has been proposed to contribute to the pathogenesis of choroidal neovascularization (CNV) in AMD. The study was conducted to determine whether treatment with clodronate liposomes (CL(2)MDP-lip), which cause depletion of blood monocytes and lymph node macrophages, diminishes the severity of neovascularization in a mouse model of laser-induced CNV. Laser-induced CNV was performed in female 16-month-old C57BL/6 mice. Macrophages were depleted by use of CL(2)MDP-lip intraperitoneally and subcutaneously 72 and 24 hours before and every 2 to 3 days after laser injury. Control mice received injections of either PBS alone or PBS liposomes. Blood monocyte and choroidal macrophage depletion were documented by flow cytometry and choroidal flatmount preparation analysis, respectively. Two weeks after laser injury, mice were injected intravenously with fluoresceinated dextran. The right eyes were removed and prepared for flatmount analysis of CNV surface area (in relative disc areas or DA), vascularity (relative fluorescence), and cellularity (propidium iodide stain). The mice were then perfused with 10% formaldehyde, and the left eyes were removed for histopathology. The means of the various parameters for four CNV lesions per eye were calculated. Fluorescein angiography was also performed. Flow cytometry of circulating monocytes and immunohistochemical analysis of choroidal macrophage density confirmed the effective depletion of blood monocytes and choroidal macrophages respectively in CL(2)MDP-lip-treated mice. Compared with the control, flatmount analysis of macrophage depleted mice demonstrated a significant reduction in size of the CNV area (2.8 +/- 0.5 DA vs. 1.4 +/- 0.1 DA; P < 0.043). The treated group also revealed less vascularity (1.6 +/- 0.1 units vs. 1.1 +/- 0.0 units; P < 0.0092) and cellularity of CNV lesions (3.3 +/- 0.6 DA vs. 1.7 +/- 0.1 DA, P < 0.04). Histopathology revealed that, in the macrophage-depleted group, CNV was smaller in diameter (1270 +/- 73 pixels vs. 770 +/- 82 pixels, P < 0.0006) and thickness (120 +/- 7 pixels vs. 96 +/- 7 pixels, P < 0.019). Macrophage depletion using CL(2)MDP-lip reduces size, cellularity, and vascularity of CNV. This observation supports the hypothesis that macrophages contribute to the severity of CNV lesions.
                Bookmark

                Author and article information

                Contributors
                thomas.langmann@uk-koeln.de
                hneuman1@uni-bonn.de
                Journal
                EMBO Mol Med
                EMBO Mol Med
                10.1002/(ISSN)1757-4684
                EMMM
                embomm
                EMBO Molecular Medicine
                John Wiley and Sons Inc. (Hoboken )
                1757-4676
                1757-4684
                22 December 2016
                February 2017
                : 9
                : 2 ( doiID: 10.1002/emmm.v9.2 )
                : 154-166
                Affiliations
                [ 1 ] Laboratory for Experimental Immunology of the Eye Department of OphthalmologyUniversity of Cologne CologneGermany
                [ 2 ] Therapeutic Research Group OphthalmologyBayer Pharma AG WuppertalGermany
                [ 3 ] Institute of Reconstructive Neurobiology University Hospital BonnUniversity of Bonn BonnGermany
                [ 4 ]Leibniz Institute for Natural Product Research and Infection Biology JenaGermany
                [ 5 ] Institute of Molecular Medicine University Hospital BonnUniversity of Bonn BonnGermany
                [ 6 ] Gene Center and Department of BiochemistryLudwig‐Maximilians‐Universität München MunichGermany
                Author notes
                [*] [* ] Corresponding author. Tel: +49 221 478 7324; E‐mail: thomas.langmann@ 123456uk-koeln.de

                Corresponding author. Tel: +49 228 6885 541; E‐mail: hneuman1@ 123456uni-bonn.de

                [†]

                These authors contributed equally to this work

                Author information
                http://orcid.org/0000-0001-6826-529X
                http://orcid.org/0000-0002-5071-5202
                Article
                EMMM201606627
                10.15252/emmm.201606627
                5286381
                28003336
                b1f3930b-1cd4-4ca1-b1f3-53926988cc9f
                © 2016 The Authors. Published under the terms of the CC BY 4.0 license

                This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 24 May 2016
                : 21 November 2016
                : 22 November 2016
                Page count
                Figures: 7, Tables: 0, Pages: 13, Words: 11097
                Funding
                Funded by: Deutsche Forschungsgemeinschaft
                Award ID: DFG‐KFO177
                Award ID: DFG‐SFB704
                Award ID: DFG‐NE507/14‐1
                Award ID: DFG‐FOR2240
                Award ID: DFG‐LA1203/9‐1
                Award ID: DFG‐Sk46/2‐2
                Award ID: DFG‐EXC1023
                Funded by: Hertie‐Foundation
                Funded by: Hans und Marlies Stock‐Foundation
                Funded by: Bayer Pharma AG
                Award ID: 2014‐08‐1139
                Funded by: NRW‐Patent‐Validierung
                Award ID: 1506pv003b
                Funded by: Bundesministerium für Bildung und Forschung
                Award ID: VIP+ 03VP00271
                Categories
                Report
                Report
                Custom metadata
                2.0
                emmm201606627
                February 2017
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.4 mode:remove_FC converted:01.02.2017

                Molecular medicine
                age‐related macular degeneration,complement,microglia,polysialic acid,siglec,immunology,neuroscience,pharmacology & drug discovery

                Comments

                Comment on this article